MedTrace Logo

Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years

NCT00372255 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2019-05-06

Study results available
· View outcomes & findings →

Summary

The study will evaluate the immune response and the tolerability of the influenza vaccine administered in children aged 6-13 years old.

Conditions

Interventions

BIOLOGICAL

Influsplit SSW® 2005/2006

Study influenza vaccine was administered intramuscularly in the non-dominant arm

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-11-17
Primary Completion
2006-03-28
Completion
2006-03-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00372255 on ClinicalTrials.gov